Header Logo

Connection

Kathleen Moore to Neoplasm Recurrence, Local

Back to Details
This is a "connection" page, showing publications Kathleen Moore has written about Neoplasm Recurrence, Local.
Kathleen Moore
Connection Strength
4.246
Neoplasm Recurrence, Local
  1. Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary. Gynecol Oncol. 2024 Dec; 191:249-258.
    View in: PubMed
    Score: 0.765
  2. Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2020 09; 158(3):631-639.
    View in: PubMed
    Score: 0.565
  3. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018 10; 151(1):46-52.
    View in: PubMed
    Score: 0.497
  4. The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer. Cancer Chemother Pharmacol. 2018 03; 81(3):497-503.
    View in: PubMed
    Score: 0.478
  5. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer. Oncologist. 2016 08; 21(8):954-63.
    View in: PubMed
    Score: 0.428
  6. Treatment Advances in Locoregionally Advanced and Stage IVB/Recurrent Cervical Cancer: Can We Agree That More Is Not Always Better? J Clin Oncol. 2015 Jul 01; 33(19):2125-8.
    View in: PubMed
    Score: 0.398
  7. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol. 2007 May; 105(2):299-303.
    View in: PubMed
    Score: 0.224
  8. Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016. Gynecol Oncol. 2024 07; 186:61-68.
    View in: PubMed
    Score: 0.184
  9. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. Gynecol Oncol. 2021 11; 163(2):274-280.
    View in: PubMed
    Score: 0.154
  10. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol. 2018 08; 150(2):274-281.
    View in: PubMed
    Score: 0.123
  11. Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182.
    View in: PubMed
    Score: 0.121
  12. The impact of obesity on surgical staging, complications, and survival with uterine cancer: a Gynecologic Oncology Group LAP2 ancillary data study. Gynecol Oncol. 2014 Apr; 133(1):23-7.
    View in: PubMed
    Score: 0.092
  13. Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence. Gynecol Oncol. 2010 Jan; 116(1):10-4.
    View in: PubMed
    Score: 0.068
  14. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2023 03; 170:241-247.
    View in: PubMed
    Score: 0.042
  15. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 11; 147(2):283-290.
    View in: PubMed
    Score: 0.029
  16. A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 05; 145(2):236-242.
    View in: PubMed
    Score: 0.028
  17. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Feb; 140(2):204-9.
    View in: PubMed
    Score: 0.026
  18. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015 Jun; 137(3):485-9.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.